In the first large, long-term randomized trial of an intervention designed to improve aromatase inhibitor adherence, the study team, led by Dawn Hershman, MD, MS, found that text message reminders were not an effective strategy.
The Community Outreach and Engagement Office (COE) at the Herbert Irving Comprehensive Cancer Center (HICCC) brings together a team of experienced researchers, clinicians and community health educators with the mission of reducing the burden of cancer and cancer disparities, specifically in the center’s catchment area.
Aaron Garcia is a graduate student at Columbia University’s School of Nursing who participated in the 2019 Velocity Ride to End Cancer. Set to graduate this summer, he now finds himself working as a nurse technician at NewYork-Presbyterian Hospital, assisting healthcare workers on the COVID-19 front lines.
Meet HICCC member Hiroshi Nakagawa, MD, PhD, who developed the first transgenic mouse model of esophageal squamous cell carcinoma and whose longstanding research in gastrointestinal cancers aims to deliver on the promise of precision oncology.
Dr. Matthew Dallos and colleagues have opened the first clinical trial testing an anti-IL-8 compound as a potential therapy against COVID-19. This phase 2 study provides COVID-positive cancer patients, who are often excluded from ongoing COVID-19 trials, with a potential option to participate in a COVID-19 clinical trial.
In a new study, Christine Rohde, MD, MPH, FACS, and her colleagues found that under the Affordable Care Act, Medicaid coverage expanded, providing lower-income women with improved access to mammograms.